Filings monitor · MRNA

What Moderna, Inc.'s SEC filings said

10-Q for 2026Q3, filed 6 Nov 2026, and 2 8-Ks since. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. Guidance / Outlook89 · importance in its document · 8-K exhibit · 6 Nov 2026
   For 2026, Moderna raised expected total revenue growth to 15%–25%, from its previous outlook of up to 10%, and expects revenue to be split approximately equally between the United States and international markets. It reduced expected…
2. Net Income and Profitability79 · importance in its document · 8-K exhibit · 6 Nov 2026
   Moderna reported third-quarter 2026 net income of $162 million, compared with a $200 million net loss in the third quarter of 2025, a $362 million year-over-year improvement. Diluted EPS was $0.38, compared with a loss per share of $0.51…
3. Convertible Notes and Capped Calls71 · importance in its document · 10-Q · 2026Q3
   In September 2026, Moderna issued $3.0 billion of 0.00% Convertible Senior Notes due 2032 and received approximately $3.0 billion in net proceeds. The notes mature in March 2032 and may be settled in cash, common shares, or a combination,…
4. Litigation Settlement Exposure71 · importance in its document · 10-Q · 2026Q3
   In March 2026, Moderna agreed to settle worldwide Arbutus/Genevant litigation concerning Spikevax and mRESVIA, also obtaining certainty for its infectious-disease portfolio, including mNEXSPIKE, mCOMBRIAX, and mFLUSIVA, with no future…
5. Liquidity and Cash Position69 · importance in its document · 10-Q · 2026Q3
   At September 30, 2026, Moderna reported $1.195 billion of cash and cash equivalents and $6.781 billion of available-for-sale securities at estimated fair value, for approximately $7.976 billion in combined cash and securities. Cash and…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 6 Nov 2026

Full report · Filing on EDGAR

• Convertible Notes and Capped CallsImportance 71
  In September 2026, Moderna issued $3.0 billion of 0.00% Convertible Senior Notes due 2032 and received approximately $3.0 billion in net proceeds. The notes mature in March 2032 and may be settled in cash, common…
• Litigation Settlement ExposureImportance 71
  In March 2026, Moderna agreed to settle worldwide Arbutus/Genevant litigation concerning Spikevax and mRESVIA, also obtaining certainty for its infectious-disease portfolio, including mNEXSPIKE, mCOMBRIAX, and…
• Liquidity and Cash PositionImportance 69
  At September 30, 2026, Moderna reported $1.195 billion of cash and cash equivalents and $6.781 billion of available-for-sale securities at estimated fair value, for approximately $7.976 billion in combined cash and…
• Revenue Performance and MixImportance 63
  Third-quarter 2026 total revenue increased 29% to $1.313 billion from $1.016 billion, while nine-month revenue increased 46% to $1.847 billion from $1.266 billion. Net product sales increased 31% to $1.273 billion for…
• Market Demand TrendsImportance 58 · +1 more on this subject
  Higher COVID vaccine sales in international markets drove the increase in Moderna’s product sales in both the third quarter and first nine months of 2026, with deliveries under long-term strategic partnerships with…
• Operating Expense TrendsImportance 58
  Research and development expense decreased $218 million, or 27%, in third-quarter 2026 and $474 million, or 20%, in the first nine months of 2026. Nine-month reductions included $246 million in clinical trial expense,…
• Product / Drug Pipeline ProgressImportance 53 · +1 more on this subject
  Moderna and Merck reported positive Phase 3 INTerpath-001 results for intismeran autogene (mRNA-4157) plus KEYTRUDA in patients with completely resected stage IIB–IV melanoma. After median follow-up of 24.6 months, the…
• Gross Margin DriversImportance 48
  Third-quarter 2026 cost of sales was $318 million, including $65 million of third-party royalties, $54 million of inventory write-downs, and $29 million of unutilized manufacturing capacity costs. Cost of sales was 24%…
• Patent Infringement LawsuitImportance 47
  Moderna and Pfizer/BioNTech have brought patent actions or asserted challenges concerning Moderna’s mRNA platform technology and vaccine designs in the United States, Germany, the Netherlands, the UK, Ireland, and…
• Guidance / OutlookImportance 44
  Moderna expects product sales to return to growth in 2026, supported by the full-year impact of long-term strategic partnerships with government entities. For 2026, it anticipates a modest decrease in cost of sales…
• Operating Cash Flow TrendsImportance 44
  Net cash used in operating activities was $2.7 billion for the nine months ended September 30, 2026, reflecting a $2.0 billion net loss, $527 million of non-cash adjustments, and a $1.3 billion net change in assets and…
• Outstanding IndebtednessImportance 44
  In November 2025, Moderna entered a credit agreement providing for a $1.5 billion term-loan facility and had drawn $600 million as of September 30, 2026. The facility includes $400 million of delayed-draw commitments…

8-K filings last 12 months

• Other officer change13 Nov 2026 · 8-K Item 5.02 · Routine · rule score 15
  “On November 13, 2026 , Moderna, Inc. (the “Company”) entered into a Transitional Services and Retirement Agreement (the “Retirement Agreement”) with Shannon Thyme Klinger, the Company’s Chief Legal Officer, that sets forth the terms of…”
• Guidance raised6 Nov 2026 · 8-K Item 2.02 · Flagged · rule score 60
  ““Building on this momentum, we increased our full-year revenue growth outlook to 15%-25%, while continuing to reduce costs and strengthen our balance sheet.”
  Read from the attached exhibit: Guidance / Outlook · Net Income and Profitability · Outstanding Indebtedness
• Management change (filing not read)30 Sept 2026 · 8-K Item 5.02 · Routine · rule score 20
  Read from the attached exhibit: Product / Drug Pipeline Progress · Manufacturing And Capacity · Leadership Transition
• Equity issuance · New debt1 Sept 2026 · 8-K Items 1.01, 2.03, 3.02 · Routine · rule score 40
  Read from the attached exhibit: Senior Notes Issuance · Convertible Notes Offering · Capped Call Transactions
• Results (release not read)31 Jul 2026 · 8-K Item 2.02 · Routine · rule score 20
  Read from the attached exhibit: Guidance / Outlook · Litigation Settlement Exposure · Gross Margin Drivers
• Management change (filing not read)8 Jul 2026 · 8-K Item 5.02 · Routine · rule score 20
  Read from the attached exhibit: Leadership Transition · Guidance / Outlook
• Results (release not read)1 May 2026 · 8-K Item 2.02 · Routine · rule score 20
• Results (release not read)13 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20
• Results (release not read)12 Jan 2026 · 8-K Item 2.02 · Routine · rule score 20
• New debt24 Nov 2025 · 8-K Items 1.01, 2.03 · Routine · rule score 25

Earlier reports

• 10-Q · 2026Q2filed 31 Jul 2026
  Liquidity and Cash Position · Litigation Settlement Exposure · Market Demand Trends

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.